secwatch.observer — SEC 8-K summary
======================================

Issuer:     Summit Therapeutics Inc. (SMMT)
CIK:        0001599298
Form:       8-K
Filed at:   2024-09-12T23:59:59+00:00
Accession:  0001193125-24-217618
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Summit Therapeutics raises $235M in private placement led by insiders at $22.70/share
--------------------------------------------------------------------------------

- Sold 10.35M shares at $22.70, the closing price on Sept 11; aggregate gross proceeds ~$235M.
- $79M raised from insiders including CEO Robert Duggan, Dr. Zanganeh, Soni, Anand, and director Jeff Huber.
- Remaining $156M from multiple leading biopharma institutional investors; no bankers' fees.
- Proceeds to advance ivonescimab clinical development in NSCLC and other cancers, plus working capital.
- Company will file a resale registration statement with SEC after closing expected by Sept 18, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1599298/000119312524217618/0001193125-24-217618-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1599298/000119312524217618/d799002d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-217618

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer